Pharmaceutical innovation between scientific opportunities and economic constraints

被引：18

作者：

Drews, J ^{[1
]}

Ryser, S ^{[1
]}

机构：

[1] HOFFMANN LA ROCHE AG,CH-4070 BASEL,SWITZERLAND

来源：

DRUG DISCOVERY TODAY | 1997年 / 2卷 / 09期

关键词：

D O I：

10.1016/S1359-6446(97)01086-6

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

New drugs are only developed when sales expectations appear to match the rising expenditures for development. The repertoire of diseases that are seriously addressed by large pharmaceutical companies is shrinking, Genomics offers the promise of inventing and developing more selective therapies for a large number of diseases, but such increases in selectivity almost inevitably lead to therapeutics aimed at smaller patient populations. Scientific opportunity on the one hand and economic constraints on the other are forcing pharmaceutical R&D in different directions. This study tries to quantify the problem and to identify mechanisms through which the apparent conflict may be resolved.

引用

页码：365 / 372

页数：8

共 12 条

[1]

*BOST CONS GROUP, 1996, SUST INN US PHARM IN

[2] COST OF INNOVATION IN THE PHARMACEUTICAL-INDUSTRY [J].

DIMASI, JA ;

HANSEN, RW ;

GRABOWSKI, HG ;

LASAGNA, L .

JOURNAL OF HEALTH ECONOMICS, 1991, 10 (02) :107-142

[3] Genomic sciences and the medicine of tomorrow [J].

Drews, J .

NATURE BIOTECHNOLOGY, 1996, 14 (11) :1516-&

[4]

DREWS J, IN PRESS NAT BIOTECH

[5]

DREWS J, IN PRESS GENETIC BAS

[6]

HANSEN RW, 1979, PHARM DEV PROCESS ES

[7]

LIFTON R, IN PRESS GENETIC BAS

[8]

MOSSINGHOFF GJ, 1995, DRUG INF J, V29, P1077

[9]

SCHWARTZ H, 1997, SCRIP MAGAZINE 0315

[10] Novartis' role in 21st century drug development [J].

Vasella, D .

NATURE BIOTECHNOLOGY, 1997, 15 (06) :485-485

← 1 2 →